N. Skorodin

Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2

R. Petrak, B. Harting, V. Chundi, 2020, medRxiv.

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

R. Petrak, B. Harting, V. Chundi, 2021, Critical care explorations.

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

R. Petrak, B. Harting, D. Vais, 2020, Clinical and translational science.

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

R. Petrak, B. Harting, D. Vais, 2020, medRxiv.

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

Apoorv Kalra, R. Petrak, K. Shah, 2020, Infectious Diseases and Therapy.

Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program

R. Petrak, B. Harting, V. Chundi, 2016, Open forum infectious diseases.